Related Experiment Video
Updated: Apr 7, 2026
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
Cognitive and fusion MRI-Targeted prostate biopsies: A multicenter comparative analysis in 485 patients
Objectives:
This multicenter study aimed to compare the diagnostic performance of cognitive registration targeted biopsy (Cog-Tb) and MRI-transrectal ultrasound fusion targeted biopsy (Fus-Tb) in men with Prostate Imaging Reporting and Data System (PI-RADS) ≥3 lesions.
Materials And Methods:
Men with PSA ≥ 3 ng/mL and/or abnormal digital rectal examination findings who had mpMRI lesions scored as PI-RADS ≥3 were included. This was a retrospective multicenter study, and the Cog-Tb and Fus-Tb groups were obtained from non-contemporary time periods and from different operators (Cog-Tb performed by urologists, Fus-Tb by a dedicated interventional radiologist). Atotal of 267 patients who underwent Cog-Tb and 218 who underwent Fus-Tb were retrospectively analyzed. At least two targeted cores were obtained from each mpMRI-defined lesion, in addition to 10-12 systematic cores. csPCa was defined as International Society of Urological Pathology (ISUP) Grade Group ≥2. Patients were stratified using a PSAd cutoff value of 0.15. In addition, a predefined stratified analysis by PI-RADS category (3 vs. 4-5) was performed, and odds ratios with 95% confidence intervals were calculated to assess independent predictors of csPCa.
Results:
There was no significant difference between Cog-Tb and Fus-Tb in the detection of ISUP ≥ 2 prostate cancer (p = 0.91). In the PI-RADS 3 subgroup, PSAd values were significantly higher in patients with ISUP ≥ 2 compared with those with benign or ISUP 1 pathology for both Cog-Tb (p = 0.02) and Fus-Tb (p = 0.04). Similarly, in the PI-RADS 4-5 subgroup, PSAd levels were significantly higher in patients with ISUP ≥ 2 disease for both biopsy techniques (p = 0.01). Multivariate logistic regression showed that biopsy modality was not an independent predictor of csPCa (OR 1.4, 95% CI 0.8-2.5). In contrast, both PSAd (OR 5.9, 95% CI 2.6-13.1) and PI-RADS category (OR 6.8, 95% CI 3.4-13.4) were strong independent predictors of csPCa.
Conclusion:
Cog-Tb and Fus-Tb demonstrated comparable effectiveness in detecting csPCa in patients with PI-RADS ≥3 lesions, particularly when PSAd ≥0.15. In settings lacking fusion technology, Cog-Tb performed by experienced clinicians remains a reliable and cost-effective alternative.
